Astellas Awards Future Innovator Prize to DeepSeq.AI and Serna Bio
Astellas Pharma and MBC BioLabs have announced DeepSeq.AI and Serna Bio as the recipients of the 2025 Astellas Future Innovator Prize. Announced in a press release, the award provides these companies with a year-long access to MBC BioLabs' state-of-the-art facilities in San Francisco, along with the expertise of Astellas to advance their research.
The prize, now in its sixth year, is designed to support biotech startups in accelerating their early research efforts. DeepSeq.AI and Serna Bio were selected from over 50 applicants based on the innovative nature of their research and the potential therapeutic impact of their work. DeepSeq.AI focuses on AI-driven large molecule discovery, while Serna Bio specializes in AI-enabled drug discovery targeting RNA structures.
This initiative by Astellas aims to foster scientific breakthroughs that could transform patient care globally, particularly in fields like oncology and infectious diseases. The collaboration with MBC BioLabs offers these startups a vibrant community and expert mentorship to help bring their pioneering ideas to fruition.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 31 AI Agent Controls Brain Injection in Live Mouse After Claude Opus Refuses Oct 31 Patient Sues Allegheny Health Network and Highmark Over Abridge AI Recordings Oct 31 OpenAI Releases GPT-Rosalind-6 for Approved Biology Researchers Oct 30 Surveys Find Widespread AI Chatbot Use Among Teens and Tweens Oct 30 Widow Sues OpenAI and Luka Over Husband's SuicideLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read moreYou may also like
AstraZeneca and Oracle Partner on AI for Clinical Trials
Atlas Bio raises $12.5 million for virtual drug trials
BioStack Raises $9.5 Million for Medical AI Data Network
Flagship Pioneering Merges Three Biotech Platforms Into Etcelera
ARPA-H Funds $28.6 Million AI Protein Research Project
Daily AI Brief: the AI news that matters, in your inbox.